Complete response of a locally advanced pulmonary hepatoid adenocarcinoma patient to perioperative XELOX-containing chemoimmunotherapy
作者机构：The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)HangzhouZhejiang 310022China Institute of Basic Medicine and Cancer(IBMC)Chinese Academy of SciencesHangzhouZhejiang 310022China Department of Thoracic Medical OncologyZhejiang Cancer HospitalHangzhouZhejiang 310022China Department of OncologyThe Second Clinical Medical College of Zhejiang Chinese Medical UniversityHangzhouZhejiang 310053China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2024年第11卷第1期
页 面：1-3页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：adenocarcinoma patient lung
摘 要：With morphological features resembling hepatocellular carcinoma,hepatoid adenocarcinoma of the lung(HAL)is a rare and aggressive subtype of lung cancer with a 5-year survival of only 8%.1 Most HAL patients present increased serum alpha-fetoprotein(AFP)levels that are commonly related to poor *** insights into HAL have come from case series or reports,and TP53 is frequently mutated in *** heterogeneity of HAL complicates the *** no established standard,the management of HAL is modeled on that of classical lung adenocarcinoma,although with dismal outcomes.2 Herein,we reported the effective management of a stage IIIb HAL patient with perioperative chemoimmunotherapy and curative-intent *** patient remained disease-free and minimal residual disease(MRD)-negative for more than one year after surgery.
维普期刊数据库